Literature DB >> 34508637

Lysosomal amino acid transporters as key players in inflammatory diseases.

Noriko Toyama-Sorimachi1, Toshihiko Kobayashi1.   

Abstract

Controlling inflammation can alleviate immune-mediated, lifestyle-related and neurodegenerative diseases. The endolysosome system plays critical roles in inflammatory responses. Endolysosomes function as signal transduction hubs to convert various environmental danger signals into gene expression, enabling metabolic adaptation of immune cells and efficient orchestration of inflammation. Solute carrier family 15 member A3 (SLC15A3) and member A4 (SLC15A4) are endolysosome-resident amino acid transporters that are preferentially expressed in immune cells. These transporters play essential roles in signal transduction through endolysosomes, and the loss of either transporter can alleviate multiple inflammatory diseases because of perturbed endolysosome-dependent signaling events, including inflammatory and metabolic signaling. Here, we summarize the findings leading to a proof-of-concept for anti-inflammatory strategies based on targeting SLC15 transporters. © The Japanese Society for Immunology. 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  amino acid transporter; endolysosome systems; immunometabolism; inflammatory signals; innate immune cells

Mesh:

Substances:

Year:  2021        PMID: 34508637     DOI: 10.1093/intimm/dxab069

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  2 in total

1.  The fission yeast FLCN/FNIP complex augments TORC1 repression or activation in response to amino acid (AA) availability.

Authors:  Isabel A Calvo; Shalini Sharma; Joao A Paulo; Alexander O D Gulka; Andras Boeszoermenyi; Jingyu Zhang; Jose M Lombana; Christina M Palmieri; Laura A Laviolette; Haribabu Arthanari; Othon Iliopoulos; Steven P Gygi; Mo Motamedi
Journal:  iScience       Date:  2021-10-23

2.  Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.

Authors:  Marianna Buttarelli; Alessandra Ciucci; Fernando Palluzzi; Giuseppina Raspaglio; Claudia Marchetti; Emanuele Perrone; Angelo Minucci; Luciano Giacò; Anna Fagotti; Giovanni Scambia; Daniela Gallo
Journal:  J Exp Clin Cancer Res       Date:  2022-02-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.